key: cord-0859115-xyzncyps
authors: Furlan, Roberto
title: A Tolerizing mRNA Vaccine against Autoimmunity?
date: 2021-02-10
journal: Mol Ther
DOI: 10.1016/j.ymthe.2021.02.003
sha: ec2c91723b7f51230186e609f2f3fa080d275d3f
doc_id: 859115
cord_uid: xyzncyps

nan

Vaccines based on mRNA are new tools in the fight against infectious disease and have received much attention in the present pandemic. In fact, the first two approved coronavirus disease 2019 (COVID-19) vaccines in the United States are mRNA vaccines. A recent paper in Science now shows that this technology, which has been optimized to induce strong, protective immune responses against specific pathogens, might be adaptable to achieve just the opposite, which is to achieve antigen-specific immune tolerance to treat autoimmune diseases. 1 As shown in the upper panel of Figure 1 , the method of mRNA vaccination is typically based on injection into the muscle of a mRNA encoding a viral protein encapsulated in liposomes made of lipids with inherent pro-inflammatory activity. These nanoparticles will be taken up by antigen presenting cells (APCs) in the tissue, which will also be activated by the lipid-mediated pro-inflammatory signals and the engagement of the Toll-like receptor 7 (TLR7) by extracellular RNA that is generated in the site of injection by breakage of some liposomes. While migrating to the lymph node, APCs will subsequently translate the mRNA to its corresponding protein and load it on their major histocompatibility complex (MHC) class I or MHC class II molecules, depending on the processing and route of uptake. In the lymph node, APCs will eventually encounter a T cell specific for the viral antigen. Successful activation of the antigen-specific T cells occurs through appropriate costimulation provided by the APCs, which themselves have been activated by the pro-inflammatory signals received at the injection site. These soluble signals are most likely also drained to the lymph node along with the APCs. 2 Costimulation is crucial because, without it, antigen presentation results in antigen-specific tolerization or even clonal deletion of antigen-specific T cells. 3 Krienke et al. 1 have exploited this latter principle to induce antigen-specific tolerization in a mouse model of the autoimmune disease multiple sclerosis. The mouse model of multiple sclerosis is called experimental autoimmune encephalomyelitis (EAE) and is based on the induction of an autoimmune reaction against brain and spinal cord oligodendrocytes by immunization with central myelin antigens. As shown in the lower panel of Figure 1 , to achieve tolerization, the authors encapsulated an mRNA encoding a myelin antigen in liposomes made of lipids devoid of pro-inflammatory activity. Importantly, the authors have also synthesized the mRNA replacing the nucleotide uridine with 1-methylpseudouridine (m1J), with the result that this m1J mRNA can induce protein translation but cannot engage TLR7. Finally, injection of these liposomes into the blood stream has ensured the uptake by circulating or lymphoid tissue-resident APCs, but avoided the potential tissuederived danger signals, and draining to the same lymph node as the targeted APCs. This strategy was not only highly effective in treating EAE induced by the very same antigen used to tolerize, but also inhibited EAE induced by a different antigen. It appears that cross tolerization of tissue-specific autoimmune T cells was achieved without impairing the overall ability of the immune system to mount an appropriate immune response to a new antigen. Several strategies have been explored to induce immune Liposomes constituted using pro-inflammatory lipids and carrying a viral antigen mRNA are injected in muscles to induce local antigen presenting cells (APCs) to uptake and translate the mRNA to its corresponding protein in a pro-inflammatory environment, consequently inducing downstream activation of antigen-specific T cells (upper panel). In contrast, non-inflammatory liposomes injected in the blood to deliver a mRNA that lacks danger signals results in induction of antigen-specific T cell tolerizance and inhibition of autoimmunity (lower panel). tolerance in autoimmune diseases, some of which have been tested also in humans with variable, sometimes paradoxical, results. 4 This novel approach has now been tested in inbred mice strains, in a very welldefined model of autoimmunity, induced by known antigens. However, it has not yet been tested in EAE induced by immunization with spinal cord homogenate, which would have led to a plethora of different autoreactivities more similar to most human autoimmune diseases. If, however, the principle of cross-tolerization holds true also in complex human autoimmunity and the tolerogenic vaccination does not result in accidental activation against the delivered antigen, then this approach would constitute a powerful and flexible new tool to treat autoimmunity. After all, there is an enormous unmet clinical need for treatment of autoimmune diseases, which are estimated to affect about 4% of the global human population.

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

mRNA vaccines -a new era in vaccinology